CAMBRIDGE, Mass.–(BUSINESS WIRE)–Stylus Medicine, Inc. (“Stylus”), a biotechnology company dedicated to developing transformative in vivo genetic medicines, today announced that Emile Nuwaysir, Ph.D., chairman and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 5:00 p.m. PT. About Stylus Medicine Stylus Medicine is developing transformative … [Read more…]

EDINBURGH, Scotland–(BUSINESS WIRE)–RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis … [Read more…]

MARSEILLE, France–(BUSINESS WIRE)–#immunotherapy–Regulatory News: Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well … [Read more…]

Ad hoc announcement pursuant to Art. 53 LR GENEVA–(BUSINESS WIRE)–Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today terminated its definitive merger agreement with STAAR Surgical Company (NASDAQ: STAA) announced on August 5, 2025. “Throughout this process we remained disciplined with our views on price and risk. Moving … [Read more…]

PASADENA, Calif.–(BUSINESS WIRE)–$arwr–Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced its intention to offer, subject to market and other conditions, $500 million aggregate principal amount of convertible senior notes due 2032 (the “notes”) and $200 million of common stock in separate public offerings registered under the Securities Act of 1933, as amended. Arrowhead also expects to … [Read more…]

BEDFORD, Mass.–(BUSINESS WIRE)–Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “The Global Nanobubbles Market 2026-2036” report has been added to ResearchAndMarkets.com’s offering. The Global Nanobubbles Market Report 2026-2036 provides detailed analysis, revenue forecasts, and strategic insights into the rapidly evolving nanobubble industry from 2026 through 2036. This report delivers actionable intelligence for investors, manufacturers, end users, and stakeholders seeking to understand market dynamics, … [Read more…]

SEATTLE–(BUSINESS WIRE)–Molina Healthcare of Washington (“Molina”), in collaboration with The MolinaCares Accord (“MolinaCares”), presented a $75,000 grant to the Seattle Indian Health Board (“SIHB”) to support the launch of the Thunderbird Treatment Center—a 92-bed residential treatment facility opening on Vashon Island. The funding will benefit the completion of the center’s new location. Substance use disorder … [Read more…]

– Veligrotug BLA accepted for thyroid eye disease (TED) with PDUFA target action date of June 30, 2026 under Priority Review; commercial preparations on track – – Topline phase 3 results for subcutaneous elegrobart (VRDN-003) on track for Q1 2026 for REVEAL-1 and Q2 2026 for REVEAL-2 for active and chronic TED, respectively – – … [Read more…]

Novel capsid technology to enable convenient delivery in the doctor’s office of IKAR-003 for intermediate AMD, designed to prevent progression to sight-threatening disease NORWICH, England & CHICAGO–(BUSINESS WIRE)–#BioTechNews–Ikarovec Ltd, which is developing dual-pathway gene therapies for vision-threatening retinal diseases, and VectorBuilder, a global leader in gene delivery technologies, have entered into an exclusive worldwide option … [Read more…]